Jasper Therapeutics
JSPR
44 hedge funds and large institutions have $169M invested in Jasper Therapeutics in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 14 increasing their positions, 2 reducing their positions, and 4 closing their positions.
1,664% more capital invested
Capital invested by funds: $9.57M → $169M (+$159M)
600% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 2
575% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 4
156% more call options, than puts
Call options by funds: $182K | Put options by funds: $71K
100% more funds holding
Funds holding: 22 → 44 (+22)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
3.1% more ownership
Funds ownership: 5.46% → 8.56% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$18.3M |
| 2 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$16.2M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$14.8M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$13.8M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
-$155K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$103K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$38K |
| 4 |
VF
Virtu Financial
New York
|
-$7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6K |
JSPR Hedge Fund Activity: Q1 2023 in Review
44 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2023, worth a combined $169M — up 1,664% from $9.57M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new JSPR positions and 4 closed out — a net gain of 23 holders — while 14 added to existing stakes and 2 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $18.3M. The largest seller was Forefront Analytics, cutting an estimated $155K.
- 44 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2023, up from 22 in Q4 2022.
- Funds reported $169M of Jasper Therapeutics stock for Q1 2023, up 1,664% quarter-over-quarter.
- 27 funds opened new Jasper Therapeutics positions in Q1 2023 and 4 closed out, a net change of +23 holders.
- The largest Jasper Therapeutics buyer in Q1 2023 was BVF Inc, an estimated $18.3M added.
- The largest Jasper Therapeutics seller in Q1 2023 was Forefront Analytics, an estimated $155K sold.
Based on aggregated 13F filings for Q1 2023.